HomeCompareHRASF vs PFE

HRASF vs PFE: Dividend Comparison 2026

HRASF yields 4.15% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRASF wins by $346.4K in total portfolio value
10 years
HRASF
HRASF
● Live price
4.15%
Share price
$4.10
Annual div
$0.17
5Y div CAGR
48.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$396.0K
Annual income
$209,990.84
Full HRASF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — HRASF vs PFE

📍 HRASF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHRASFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HRASF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HRASF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HRASF
Annual income on $10K today (after 15% tax)
$352.44/yr
After 10yr DRIP, annual income (after tax)
$178,492.21/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, HRASF beats the other by $156,172.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HRASF + PFE for your $10,000?

HRASF: 50%PFE: 50%
100% PFE50/50100% HRASF
Portfolio after 10yr
$222.8K
Annual income
$118,124.78/yr
Blended yield
53.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HRASF
No analyst data
Altman Z
1.5
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HRASF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHRASFPFE
Forward yield4.15%6.13%
Annual dividend / share$0.17$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.9%13.2%
Portfolio after 10y$396.0K$49.6K
Annual income after 10y$209,990.84$26,258.71
Total dividends collected$354.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HRASF vs PFE ($10,000, DRIP)

YearHRASF PortfolioHRASF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,317$617.39$9,153$693.39+$2.2KHRASF
2$13,082$972.34$8,593$849.25+$4.5KHRASF
3$15,562$1,564.06$8,336$1,066.78+$7.2KHRASF
4$19,240$2,589.11$8,437$1,384.80+$10.8KHRASF
5$25,042$4,454.64$9,013$1,875.40+$16.0KHRASF
6$34,863$8,068.20$10,306$2,680.72+$24.6KHRASF
7$52,934$15,631.00$12,820$4,101.38+$40.1KHRASF
8$89,667$33,027.23$17,673$6,826.70+$72.0KHRASF
9$173,797$77,853.58$27,543$12,591.86+$146.3KHRASF
10$395,954$209,990.84$49,560$26,258.71+$346.4KHRASF

HRASF vs PFE: Complete Analysis 2026

HRASFStock

Hera S.p.A., a multi-utility company, engages in the waste management, water services, and energy businesses in Italy. It engages in the sale and distribution of methane and natural gas, as well as in the district heating and heating management business; generation, distribution, and sale of electricity; aqueduct, purification, and sewage services related to water; waste collection, treatment, recycling, and disposal services; and provision of public lighting, telecommunications, and other services. The company's water services include activities related to water collection, drinking water treatment, and distribution for civil and industrial applications, as well as sewerage and sewage treatment activities; and environmental services comprise sweeping, waste collection, transport, and recovery and disposal. It manages water services in 227 municipalities and serves a catchment area of approximately 3.6 million inhabitants with a water network of 35.080 kilometers; and provides gas with a network covering approximately 19,953 kilometers. The company was founded in 2002 and is headquartered in Bologna, Italy.

Full HRASF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HRASF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HRASF vs SCHDHRASF vs JEPIHRASF vs OHRASF vs KOHRASF vs MAINHRASF vs JNJHRASF vs MRKHRASF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.